Secarna Pharmaceuticals

Secarna Pharmaceuticals company information, Employees & Contact Information

Secarna Pharmaceuticals is a biopharmaceutical company redefining the discovery and development of best-in-class oligonucleotide therapeutics addressing high unmet medical needs in immuno-oncology and immunology, as well as viral, neurodegenerative and cardiometabolic diseases. Secarna’s mission is to maximize the performance and output of OligoCreator, its proprietary oligonucleotide discovery and development platform, to generate highly specific, safe, and efficacious best-in-class therapeutics. With over 20 discovery and development programs, including both proprietary pipeline projects and partnered programs, Secarna focuses on targets in indications where oligonucleotide-based approaches have clear potential benefits over other therapeutic modalities. www.secarna.com

Company Details

Employees
18
Address
Am Klopferspitz 19, Martinsried,bavaria 82152,germany
Phone
+49 (0) 6421/9830050
Email
in****@****rna.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Martinsried, Bavaria
Looking for a particular Secarna Pharmaceuticals employee's phone or email?

Secarna Pharmaceuticals Questions

News

Secarna Pharmaceuticals, Scenic Biotech Enter Drug Discovery & Co-Development Pact - Contract Pharma

Secarna Pharmaceuticals, Scenic Biotech Enter Drug Discovery & Co-Development Pact Contract Pharma

Secarna Pharmaceuticals and Curie.Bio Portfolio Company Enter into Research and Option Agreement - Yahoo Finance

Secarna Pharmaceuticals and Curie.Bio Portfolio Company Enter into Research and Option Agreement Yahoo Finance

Secarna Pharmaceuticals and Vect-Horus Announce Research - GlobeNewswire

Secarna Pharmaceuticals and Vect-Horus Announce Research GlobeNewswire

EQS-News: Secarna Pharmaceuticals enters discovery and co-development agreement with Scenic Biotech to develop disease-modifying oligonucleotide therapy against a novel drug target - boerse.de - boerse.de

EQS-News: Secarna Pharmaceuticals enters discovery and co-development agreement with Scenic Biotech to develop disease-modifying oligonucleotide therapy against a novel drug target - boerse.de boerse.de

VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology - The Manila Times

VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology The Manila Times

Secarna Pharmaceuticals and Curie.Bio portfolio company enter research and option agreement - Pharmafile

Secarna Pharmaceuticals and Curie.Bio portfolio company enter research and option agreement Pharmafile

This Week’s Biopharma News: Pfizer, BioNTech, and Moderna Court Case Continues - The Medicine Maker

This Week’s Biopharma News: Pfizer, BioNTech, and Moderna Court Case Continues The Medicine Maker

Secarna: Next generation antisense therapeutics - Open Access Government

Secarna: Next generation antisense therapeutics Open Access Government

Secarna Pharmaceuticals and Orbit Discovery Enter Collaboration to Discover and Develop Peptide-conjugated Targeted Antisense Oligonucleotide Therapeutics - Business Wire

Secarna Pharmaceuticals and Orbit Discovery Enter Collaboration to Discover and Develop Peptide-conjugated Targeted Antisense Oligonucleotide Therapeutics Business Wire

Secarna aims to expand the therapeutic toolbox against cancer and improve cancer survival rates - Open Access Government

Secarna aims to expand the therapeutic toolbox against cancer and improve cancer survival rates Open Access Government

Secarna and Denali expand CNS partnership as big pharma’s demand for antisense drugs grows - BioWorld MedTech

Secarna and Denali expand CNS partnership as big pharma’s demand for antisense drugs grows BioWorld MedTech

Unraveling the potential of antisense therapies to target neuropilin 1 in the fight against cancer - Open Access Government

Unraveling the potential of antisense therapies to target neuropilin 1 in the fight against cancer Open Access Government

EQS-News: Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in debilitating autoinflammatory - boerse.de - boerse.de

EQS-News: Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in debilitating autoinflammatory - boerse.de boerse.de

Antisense therapies: A new approach to tackling challenging targets in areas of high unmet medical need - Open Access Government

Antisense therapies: A new approach to tackling challenging targets in areas of high unmet medical need Open Access Government

Top Secarna Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant